# Liz Hogan
Лучшие выпуски подкастов
Обновлено:
liz hogan (born July 1989) is an American women’s lacrosse player. Having played with the Syracuse Orange at the collegiate level, she was named to the US national team for the 2015-16 season. In 2016, she was selected by the Boston Storm as their first-ever selection in the inaugural United Women's Lacrosse League Draft.
Oncology's Biosimilar Lessons for Retina | Plus, Moving to a New OR
The companion piece to RetinUp’s previous episode on biosimilars is here, featuring an oncologist who has lived through biosimilar disruption for the past decade. Stephen "Fred" Divers, MD, CMO of the American Oncology Network, joins John and Scott to share what oncology has learned from nearly a d…
Breaking News: EyePoint's Phase 3 Topline Data Release
Breaking news: EyePoint Pharmaceuticals announced LUGANO Phase 3 topline data this morning. Duravyu, an investigational sustained-release TKI for wet AMD, did not meet its primary non-inferiority endpoint in the full dataset — confounded by nine patients in what EyePoint is calling an asymmetric co…
Jay Duker, MD, on LUGANO and What Comes Next for Duravyu and EyePoint | Plus, Miles Harper on Successful and Failed OR Innovations
Jay S. Duker, MD, President & CEO of EyePoint Pharmaceuticals, joins John and Scott to parse the LUGANO Phase 3 topline data — just three days after release. He walks through Duravyu's MOA, what the nine outlier patients in the study actually represent, why the secondary data are compelling, and wh…
Breaking News: Beacon's Gene Therapy Laru-zova Hits Primary Endpoint in VISTA for XLRP
Breaking news: Beacon Therapeutics announced positive topline data from the VISTA pivotal trial of laru-zova (laruparetigene zovaparvovec) for X-linked retinitis pigmentosa (XLRP) — the first gene therapy trial in XLRP to reach its primary endpoint.
John Kitchens, MD, and Scott Krzywonos break down…
Breaking News: Merck's Remigromig Hits Primary Endpoint in BRUNELLO for DME [Corrected]
![Breaking News: Merck's Remigromig Hits Primary Endpoint in BRUNELLO for DME [Corrected]](https://cdn-images-3.listennotes.com/podcasts/retinup-podcast/breaking-news-mercks-nYGLHrsDvA2-W1XK7cvNCDm.300x300.jpg)
Breaking news: Merck announced this morning that remigromig (MK-3000), its investigational tetravalent tri-specific Wnt pathway agonist, met the primary endpoint of the Phase 2b/3 BRUNELLO trial for diabetic macular edema. Both the 0.5 mg and 0.8 mg doses independently demonstrated non-inferiority …
Breaking News: Kodiak's DAYBREAK Hits — Zenkuda and Tabirafusp-ted Both Positive
Breaking news: Kodiak Sciences announced this morning that both Zenkuda (tarcocimab tedromer) and tabirafusp-ted (KSI-501, tabirafusp alfa tedromer) met their primary endpoints in the Phase 3 DAYBREAK study in wet AMD — non-inferiority in vision gains vs. aflibercept at 1 year. Kodiak plans a Q4 20…
The 2026 Data Recap — What to Watch at AAO Next Week
John Kitchens, MD, and Scott Krzywonos take stock of the biggest retina data readouts of 2026 — from a superiority study from Ocular Therapeutix to a Kodiak comeback and a gene therapy from Beacon that could be the first approval for an inherited retinal disease since Luxturna in 2017. Also discuss…
Breaking News: LUCIA Misses in Wet AMD — EyePoint Shifts to DME
Breaking news: EyePoint Pharmaceuticals announced this morning that LUCIA, the second pivotal Phase 3 trial of Duravyu (vorolanib, EYP-1901) for wet AMD, did not achieve the primary endpoint of statistical non-inferiority in mean change in BCVA versus on-label aflibercept. EyePoint is shifting reso…
Breaking News: Alcon Acquires Neurotech
Two pieces of news today, October 21, 2026.
Alcon announced the acquisition of Neurotech Pharmaceuticals for $550 million upfront, with additional milestone payments possible. John Kitchens, MD, and Scott Krzywonos break down why the pairing makes sense, what Alcon’s OR infrastructure could mean fo…
Big Pharma’s Retina Bets | Don D’Amico, MD, on BRUNELLO | RetinUp Turns One
RetinUp turns one year old. Before the birthday reflections, John Kitchens, MD, and Scott Krzywonos take stock of what the past eighteen months of retina acquisitions actually mean: Merck’s purchase of EyeBio for up to $3 billion, Eli Lilly’s acquisition of Adverum Biotechnologies for up to $262 mi…
ПОИСКОВАЯ СИСТЕМА ПОДКАСТОВ
Вы можете использовать наш веб-сайт для поиска подкастов3,833,744и эпизодов197,126,622по людям, местам или темам.
If I have seen further than others, it is by listening to podcasts and standing upon the shoulders of
giants.
‐ Isaac "Llamacorn" Newton
ИЗМЕНИТЬ
Спасибо, что помогаете поддерживать базу подкастов актуальной.
